RxDoctor Payments Data
★ My doctorsLook up a doctor →

David Ganeles

Psychiatry · Woodmere, NYNPI 1225123011

Payments from drug & device makers

$23,402in general payments, 2019–2025

Across 1,028 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$4K
  • Neos Therapeutics, LP$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • AbbVie$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Lundbeck LLC$2K
  • plus $7K from 16 others

What the payments were for

  • Food & beverage$23,394100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka America Pharmaceutical, Inc.148$3,590
Neos Therapeutics, LP152$3,261
Takeda Pharmaceuticals U.S.A., Inc.88$2,999
AbbVie(2 entities)123$2,370
Sunovion Pharmaceuticals Inc.94$2,226
Lundbeck LLC114$2,155
Corium, LLC64$1,572
Tris Pharma Inc79$1,543
Axsome Therapeutics, Inc.35$808
Alkermes, Inc.33$721
Arbor Pharmaceuticals, Inc.32$601
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)17$419
Almatica Pharma LLC14$309
Teva Pharmaceuticals USA, Inc.9$162
Supernus Pharmaceuticals, Inc.7$135
Shire North American Group Inc6$129
E.r. Squibb & Sons, L.L.C.1$126
Alfasigma USA, Inc.4$90
Ironshore Pharmaceuticals Inc.4$77
Vanda Pharmaceuticals Inc.2$57
Neurocrine Biosciences, Inc.1$27
Johnson & Johnson1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,402 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate12$20,153
Divalproex Sodium ErDivalproex Sodium13$2,117
Lisdexamfetamine Dimesylate11$1,638
Quetiapine Fumarate23$1,436
Vilazodone Hcl14$723
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$399
Bupropion XlBupropion Hcl20$285
Duloxetine Hcl11$282
Fluoxetine Hcl37$192
Lithium Carbonate15$162
Mirtazapine13$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$721$20,15312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Woodmere

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →